You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Express Scripts
Dow
McKesson
Baxter

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,504,669

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,504,669
Title:Spliceostatin analogs and methods for their preparation
Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
Inventor(s): Subramanyam; Chakrapani (South Glastonbury, CT), Koehn; Frank Erich (Mystic, CT), Dirico; Kenneth John (Gales Ferry, CT), Eustaquio; Alessandra S. (Old Saybrook, CT), Green; Michael Eric (Boston, MA), He; Haiyin (Mahwah, NJ), He; Min (North Potomac, MD), O\'Donnell; Christopher John (Mystic, CT), Puthenveetil; Sujiet (North Attleboro, MA), Ratnayake; Anokha (Mystic, CT), Teske; Jesse Alexander (Westerly, RI), Yang; Hui Yu (Newton, MA)
Assignee: Pfizer Inc. (New York, NY)
Application Number:14/818,455
Patent Claims:1. A method for treating cancer comprising administering to a patient an amount of a compound of formula (I): ##STR00319## wherein: a dashed line represents an optional bond; each X.sup.1 is independently selected from the group consisting of: --O--, --S-- and --NR--; each X.sup.2 is independently selected from the group consisting of: --O--, --S-- and --NR--; R.sup.1 is selected from the group consisting of: --R, --OR, --OCOR.sup.13, --OCONR.sup.14R.sup.15, --OCON(R.sup.14)NR(R.sup.15), .dbd.O (double bond to oxygen) and --NR.sup.14R.sup.15; R.sup.2 and R.sup.3 are independently selected from the group consisting of: hydrogen and C.sub.1-6alkyl; R.sup.4 and R.sup.5 are independently selected from the group consisting of: hydrogen, --OR, --NR.sup.14R.sup.15 and oxo; R.sup.6 and R.sup.7 are independently selected from the group consisting of: hydrogen, halogen, hydroxyl and C.sub.1-6alkyl optionally substituted with 1-3 substituents independently selected from hydroxyl and halogen, R.sup.6 and R.sup.7, together with the carbon atom to which they are bound, form a C.sub.2-5alkylidene optionally substituted with 1-3 substituents independently selected from R, R.sup.6 and R.sup.7 together are oxo, or R.sup.6 and R.sup.7, together with the carbon atom to which they are bound, form a 3- to 5-membered heterocycloalkyl moiety comprising 1 or 2 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur, wherein said heterocycloalkyl moiety may be optionally substituted with one to three substituents independently selected from R; R.sup.8 is hydrogen, C.sub.1-6alkyl or --OR; R.sup.9 is independently selected from --(C(R).sub.2).sub.m--C(O)OR, --(C(R).sub.2).sub.m--C(O)NR.sup.14R.sup.15, --(C(R).sub.2).sub.m--NR.sup.14R.sup.15, --(C(R).sub.2).sub.m--N(R)COR.sup.13, --(C(R).sub.2).sub.m--C(O)--SR, --(C(R).sub.2).sub.m--C(O)NR.sup.14N(R)R.sup.15, --(C(R).sub.2).sub.m--NR--C(O)--NR.sup.14R.sup.15 and (C(R).sub.2).sub.m--NR.sup.14N(R)R.sup.15; R.sup.13 is selected from the group consisting of hydrogen, C.sub.1-6alkyl, C.sub.3-8carbocyclyl, C.sub.3-8heterocyclyl, C.sub.1-6alkyl-C.sub.6-14aryl, C.sub.1-6alkyl-O.sub.5-14heteroaryl, wherein R.sup.13 is optionally substituted with --NRR or --SO.sub.2NRR; each R.sup.14 and R.sup.15 is independently selected from the group consisting of: hydrogen, hydroxyl, --NRR, --NRNR.sub.2, --C.sub.3-10carbocyclyl, --C.sub.1-6alkylene-C.sub.3-10carbocyclyl, --C.sub.3-10heterocyclyl, --C.sub.1-6alkylene-C.sub.3-10heterocyclyl, --(CH.sub.2CH.sub.2O).sub.1-6CH.sub.2CH.sub.2C(O)OR, --(CH.sub.2CH.sub.2O).sub.1-6CH.sub.2CH.sub.2NRR, --C.sub.1-6alkyl, C.sub.6-14aryl, --C.sub.1-6alkylene-C.sub.6-14aryl and --C.sub.5-14heteroaryl; or R.sup.14 and R.sup.15, together with the atom or atoms to which they are joined, form a C.sub.3-10heterocyclyl ring, wherein R.sup.14, R.sup.15, or both, or a ring formed with R.sup.14 and R.sup.15, are optionally substituted with --(C(R).sub.2).sub.m--R.sup.18 where each R.sup.18 is independently selected from (i) --NRR, (ii) --C(NRR)(C(O)OR), (iii) --S--R, (iv) aryl or heteroaryl optionally substituted with one or more of halogen, --CF.sub.3, --(C(R).sub.2).sub.m--NRR or --(C(R).sub.2).sub.m--SO.sub.2NRR, (v) --SO.sub.2R, (vi) --S--S--C.sub.1-6alkyl-C(O)OR, (vii) --SO.sub.2NRR, (viii) --C(O)NRR, (ix) --C(O)OR, (x) --C.sub.4-6 cycloalkyl optionally substituted with --NRR, --SO.sub.2NRR or --NR--C(O)(CH.sub.2).sub.0-6NRR, (xi) --R, (xii) --OR, (xiii) --N(R)NRR, (xiv) --C(O)N(R)NRR, --(C(R).sub.2).sub.m--O--NRR and --S--S--C.sub.1-6alkyl-NRR; each R is independently selected from the group consisting of: hydrogen and --C.sub.1-6alky; and each m is independently 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof, said amount being effective to that cancer.

2. The method of claim 1 where said cancer is selected from carcinomas of the bladder, breast, cervix, colon, endometrium, kidney, lung, esophagus, ovary, prostate, pancreas, skin, stomach, and testes, leukemias and lymphomas.

3. The method of claim 2 wherein said compound is selected from the group consisting of: ##STR00320## ##STR00321## ##STR00322## ##STR00323## ##STR00324## ##STR00325## ##STR00326## ##STR00327## ##STR00328## ##STR00329## ##STR00330## ##STR00331## ##STR00332## ##STR00333## or a pharmaceutically acceptable salt thereof.

4. A method for treating cancer comprising administering to a patient an amount of a compound having the formula III: (AB)-(L-P).sub.b (III) or a pharmaceutically acceptable salt thereof, wherein: L is the linker moiety L.sup.1-L.sup.2-L.sup.3, where L.sup.3 is bound to P; P is a radical of formula (I): ##STR00334## wherein: a dashed line represents an optional bond; AB is an antibody; each X.sup.1 is independently selected from the group consisting of: --O--, --S-- and --NR--; each X.sup.2 is independently selected from the group consisting of: --O--, --S-- and --NR--; each X' is CR or N; each X'' is CH--, CR--(C(R).sub.2).sub.m--NR--, CR--(C(R).sub.2).sub.m--O--; CR--(C(R).sub.2).sub.m--C(O)NR--, CR--(C(R).sub.2).sub.m--C(O)NR--NR--, CR--(C(R).sub.2).sub.m--SO.sub.2NR--, CR--(C(R).sub.2).sub.m--NR--NR--, CR--(C(R).sub.2).sub.m--NR--C(O)-- or N-- if X'' binds to L.sup.2 or an additional L.sup.3, or otherwise is O, S, CRR, CR--(C(R).sub.2).sub.m--NRR or NRR; each X''' is --(C(R).sub.2).sub.m--NR-- or CR--(C(R).sub.2).sub.m--O-- if X''' binds to L.sup.2, or otherwise is R; Y is --C(R).sub.2--, --O--, --NR-- or --S--; R.sup.1 is selected from the group consisting of: --R, --OR, --OCOR.sup.13, --OCONR.sup.14R.sup.15, --OCON(R.sup.14)NR(R.sup.15), .dbd.O (double bond to oxygen) and --NR.sup.14R.sup.15; R.sup.2 and R.sup.3 are independently selected from the group consisting of: hydrogen and C.sub.1-6alkyl; R.sup.4 and R.sup.5 are independently selected from the group consisting of: hydrogen, --OR, --NR.sup.14R.sup.15 and oxo; R.sup.6 and R.sup.7 are independently selected from the group consisting of: hydrogen, halogen, hydroxyl and C.sub.1-6alkyl optionally substituted with 1-3 substituents independently selected from hydroxyl and halogen, R.sup.6 and R.sup.7, together with the carbon atom to which they are bound, form a C.sub.2-5alkylidene optionally substituted with 1-3 substituents independently selected from R, R.sup.6 and R.sup.7 together are oxo, or R.sup.6 and R.sup.7, together with the carbon atom to which they are bound, form a 3- to 5-membered heterocycloalkyl moiety comprising 1 or 2 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur, wherein said heterocycloalkyl moiety may be optionally substituted with one to three substituents independently selected from R; R.sup.8 is hydrogen, C.sub.1-6alkyl or --OR; R.sup.9 is --(C(R).sub.2).sub.m--C(O)-- or --(C(R).sub.2).sub.m--; L.sup.1 is selected from: a bond to AB, --NR-(bond to AB) and ##STR00335## L.sup.2 is L.sup.2A-L.sup.2B-L.sup.2C or L.sup.2C-L.sup.2B-L.sup.2A where: L.sup.2A comprises one or more components selected from: --O--, --C(O)--, --C(O)NR--, --C(O)--C.sub.1-6alkyl-, --C(O)NRC.sub.1-6alkyl-, --C.sub.1-6alkyl(OCH.sub.2CH.sub.2).sub.1-6--, --C(O)--C.sub.1-6alkyl-NRC(O)--, --C(O)--C.sub.1-6alkyl(OCH.sub.2CH.sub.2).sub.1-6--, --C.sub.1-6alkyl(OCH.sub.2CH.sub.2).sub.1-6--C(O)--, --C.sub.1-6alkyl-S--S--C.sub.1-6alkyl-NRC(O)CH.sub.2--, --C.sub.1-6alkyl-(OCH.sub.2CH.sub.2).sub.1-6--NRC(O)CH.sub.2--, --C(O)--C.sub.1-6alkyl-NRC(O)C.sub.1-6alkyl-, --N.dbd.CR-phenyl-O--C.sub.1-6alkyl-, --N.dbd.CR-phenyl-O--C.sub.1-6alkyl-C(O)--, --C(O)--C.sub.1-6alkyl(OCH.sub.2CH.sub.2).sub.1-6--NRC(O)--, --C(O)--C.sub.1-6alkyl-phenyl-(NR--C(O)--C.sub.1-6alkyl).sub.1-4-, --C(O)--C.sub.1-6alkyl-(OCH.sub.2CH.sub.2).sub.1-6--NRC(O)C.sub.1-6alkyl-- , --C.sub.1-6alkyl-, --S--, --C(O)--C.sub.1-6alkyl-phenyl-NR--, --O--C.sub.1-6alkyl-S--, --C(O)--O--C.sub.1-6alkyl-S-- and (--CH.sub.2--CH.sub.2--O--).sub.1-20, or L.sup.A is absent; L.sup.2B is selected from AA.sub.0-aa, where AA is a natural or non-natural amino acid and aa is 12; and L.sup.2C comprises one or more components selected from: -PABA- and -PABC-, or L.sup.2C is absent; L.sup.3 is selected from one or more of: --C.sub.1-6alkyl-, --NR--C.sub.3-C.sub.8heterocyclyl-NR--, --NR--C.sub.3-C.sub.8carbocyclyl-NR--, --NR--C.sub.1-6alkyl-NR--, --NR-C.sub.1-6alkyl-, --S--, --NR--NR-- and --NR--C(O)--NR-- where the two R groups optionally join to form a 4-10 membered ring, --NR--C.sub.1-6alkyl-phenyl-NR--, --NR--C.sub.1-6alkyl-phenyl-SO.sub.2--NR--, --SO.sub.2--, --NR--C.sub.1-6alkyl-phenyl-C(O)--, ##STR00336## or L.sup.3 is absent; R.sup.13 is selected from the group consisting of hydrogen, C.sub.1-6alkyl, C.sub.3-8carbocyclyl, C.sub.3-8heterocyclyl, C.sub.1-6 alkyl-C.sub.6-14aryl, C.sub.1-6alkyl-C.sub.5-14heteroaryl, wherein R.sup.13 is optionally substituted with --NRR or --SO.sub.2NRR; each R.sup.14 and R.sup.15 is independently selected from the group consisting of: hydrogen, hydroxyl, --NRR, --NRNR.sub.2, --C.sub.3-10carbocyclyl, --C.sub.1-6alkylene-C.sub.3-10carbocyclyl, --C.sub.3-10heterocyclyl, --C.sub.1-6alkylene-C.sub.3-10heterocyclyl, --(CH.sub.2CH.sub.2O).sub.1-6 CH.sub.2CH.sub.2C(O)OR, --(CH.sub.2CH.sub.2O).sub.1-6CH.sub.2CH.sub.2NRR, --C.sub.1-6alkyl, C.sub.6-14aryl, --C.sub.1-6alkylene-C.sub.6-14aryl and --C.sub.5-14heteroaryl; or R.sup.14 and R.sup.15, together with the atom or atoms to which they are joined, form a C.sub.3-10heterocyclyl ring, wherein R.sup.14, R.sup.15, or both, or a ring formed with R.sup.14 and R.sup.15, are optionally substituted with --(C(R).sub.2).sub.m--R.sup.18 where each R.sup.18 is independently selected from (i) --NRR, (ii) --C(NRR)(C(O)OR), (iii) --S--R, (iv) aryl or heteroaryl optionally substituted with one or more of halogen, --CF.sub.3, --(C(R).sub.2).sub.m--NRR or --(C(R).sub.2).sub.m--SO.sub.2NRR, (v) --SO.sub.2R, (vi) --S--S--C.sub.1-6alkyl-C(O)OR, (vii) --SO.sub.2NRR, (viii) --C(O)NRR, (ix) --C(O)OR, (x) --C.sub.4-6 cycloalkyl optionally substituted with --NRR, --SO.sub.2NRR or --NR--C(O)(CH.sub.2).sub.0-6NRR, (xi) --R, (xii) --OR, (xiii) --N(R)NRR, (xiv) --C(O)N(R)NRR, (xv) --(C(R).sub.2).sub.m--O--NRR and (xiv) --S--S--C.sub.1-6alkyl-NRR; each R is independently selected from the group consisting of: hydrogen and --C.sub.1-6alkyl; and b is 1-20; and each m is independently 0, 1, 2 or 3, said amount being effective to treat cancer.

5. The method of claim 4 wherein said cancer is selected from carcinomas of the bladder, breast, cervix, colon, endometrium, kidney, lung, esophagus, ovary, prostate, pancreas, skin, stomach, and testes, leukemias and lymphomas.

6. A method for treating cancer comprising administering to a patient an amount of a compound having the formula III': (AB)-(L-P').sub.b (III') or a pharmaceutically acceptable salt thereof, wherein: L is the linker moiety L.sup.1-L.sup.2-L.sup.3, where L.sup.3 is bound to P'; P' is a radical of formula (I'): ##STR00337## wherein: a dashed line represents an optional bond; AB is an antibody; each X.sup.1 is independently selected from the group consisting of: --O--, --S-- and --NR--; each X.sup.2 is independently selected from the group consisting of: --O--, --S-- and --NR--; each X' is CR or N; each X'' is CH--, CR--(C(R).sub.2).sub.m--NR--, CR--(C(R).sub.2).sub.m--O--; CR--(C(R).sub.2).sub.m--C(O)NR--, CR--(C(R).sub.2).sub.m--C(O)NR--NR--, CR--(C(R).sub.2).sub.m--SO.sub.2NR--, CR--(C(R).sub.2).sub.m--NR--NR--, CR--(C(R).sub.2).sub.m--NR--C(O)-- or N-- if X'' binds to L.sup.2 or an additional L.sup.3, or otherwise is O, S, CRR, CR--(C(R).sub.2).sub.m--NRR or NRR; each X''' is --(C(R).sub.2).sub.m--NR-- or CR--(C(R).sub.2).sub.m--O-- if X''' binds to L.sup.2, or otherwise is R; Y is --C(R).sub.2--, --O--, --NR-- or --S--; R.sup.1 is selected from the group consisting of: --(C(R).sub.2).sub.m--C(O)--, --(C(R).sub.2).sub.m--, --OR'', --OCOR.sup.13', --OCONRR.sup.14', --OCON(R.sup.14)N(R.sup.15)--, and --NR.sup.14-- R.sup.2 and R.sup.3 are independently selected from the group consisting of: hydrogen and C.sub.1-6alkyl; R.sup.4 and R.sup.5 are independently selected from the group consisting of: hydrogen, --OR, --NR.sup.14R.sup.15 and oxo; R.sup.6 and R.sup.7 are independently selected from the group consisting of: hydrogen, halogen, hydroxyl and C.sub.1-6alkyl optionally substituted with 1-3 substituents independently selected from hydroxyl and halogen, R.sup.6 and R.sup.7, together with the carbon atom to which they are bound, form a C.sub.2-5alkylidene optionally substituted with 1-3 substituents independently selected from R, R.sup.6 and R.sup.7 together are oxo, or R.sup.6 and R.sup.7, together with the carbon atom to which they are bound, form a 3- to 5-membered heterocycloalkyl moiety comprising 1 or 2 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur, wherein said heterocycloalkyl moiety may be optionally substituted with one to three substituents independently selected from R; R.sup.8 is hydrogen, C.sub.1-6alkyl or --OR; R.sup.9 is independently selected from hydrogen, --C.sub.1-6alkyl, --(C(R).sub.2).sub.m--C(O)OR, --(C(R).sub.2).sub.m--C(O)NR.sup.14R.sup.15, --(C(R).sub.2).sub.m--NR.sup.14R.sup.15, --(C(R).sub.2).sub.m--C(O)--SR, --(C(R).sub.2).sub.m--C(O)NR.sup.14N(R)R.sup.15, --(C(R).sub.2).sub.m--NR--C(O)--NR.sup.14R.sup.15, --(C(R).sub.2).sub.m--NR.sup.14N(R)R.sup.15 and --(C(R).sub.2).sub.m--N(R)COR.sup.13; wherein R.sup.13 is hydrogen or C.sub.1-6alkyl, L.sup.1 is selected from: a bond to AB, --NR-(bond to AB) and ##STR00338## L.sup.2 is L.sup.2A-L.sup.2B-L.sup.2c or L.sup.2c-L.sup.2B-L.sup.2A where: L.sup.2A comprises one or more components selected from: --O--, --C(O)--, --C(O)NR--, --C(O)--C.sub.1-6alkyl-, --C(O)NRC.sub.1-6alkyl-, --C.sub.1-6alkyl(OCH.sub.2CH.sub.2).sub.1-6--, --C(O)--C.sub.1-6alkyl-NRC(O)--, --C(O)--C.sub.1-6alkyl(OCH.sub.2CH.sub.2).sub.1-6--, --C.sub.1-6alkyl(OCH.sub.2CH.sub.2).sub.1-6--C(O)--, --C.sub.1-6alkyl-S--S--C.sub.1-6alkyl-NRC(O)CH.sub.2--, --C.sub.1-6alkyl-(OCH.sub.2CH.sub.2).sub.1-6--NRC(O)CH.sub.2--, --C(O)--C.sub.1-6alkyl-NRC(O)C.sub.1-6alkyl-, --N.dbd.CR-phenyl-O--C.sub.1-6alkyl-, --N.dbd.CR-phenyl-O--C.sub.1-6alkyl-C(O)--, --C(O)--C.sub.1-6alkyl(OCH.sub.2CH.sub.2).sub.1-6--NRC(O)--, --C(O)--C.sub.1-6alkyl-phenyl-(NR--C(O)--C.sub.1-6alkyl).sub.1-4-, --C(O)--C.sub.1-6alkyl-(OCH.sub.2CH.sub.2).sub.1-6--NRC(O)C.sub.1-6alkyl-- , --C.sub.1-6alkyl-, --S--, --C(O)--C.sub.1-6alkyl-phenyl-NR--, --O--C.sub.1-6alkyl-S--, --C(O)--O--C.sub.1-6alkyl-S-- and (--CH.sub.2--CH.sub.2--O--).sub.1-20, or L.sup.A is absent; L.sup.2B is selected from AA.sub.0-aa, where AA is a natural or non-natural amino acid and aa is 12; and L.sup.2C comprises one or more components selected from: -PABA- and -PABC-, or L.sup.2C is absent; L.sup.3 is selected from one or more of: --C.sub.1-6alkyl-, --NR--C.sub.3-C.sub.8heterocyclyl-NR--, --NR--C.sub.3-C.sub.8carbocyclyl-NR--, --S--, --NR--NR-- and --NR--C(O)--NR-- where the two R groups optionally join to form a 4-10 membered ring, --NR--C.sub.1-6alkyl-phenyl-NR--, --NR--C.sub.1-6alkyl-phenyl-SO.sub.2--NR--, --SO.sub.2--, --NR--C.sub.1-6alkyl-phenyl-C(O)--, ##STR00339## or L.sup.3 is absent; R.sup.13' is selected from the group consisting of a bond, --C.sub.1-6alkylene-, --C.sub.3-8carbocyclyl-, --C.sub.3-8 heterocyclyl-, --C.sub.1-6alkyl-C.sub.6-14aryl-, --C.sub.1-6alkyl-C.sub.5-14heteroaryl-; each R.sup.14 and R.sup.15 is independently selected from the group consisting of: hydrogen, hydroxyl, --NRR, --NRNR.sub.2, --C.sub.3-10carbocyclyl, --C.sub.1-6alkylene-C.sub.3-10carbocyclyl, --C.sub.3-10heterocyclyl, --C.sub.1-6alkylene-C.sub.3-10heterocyclyl, --(CH.sub.2CH.sub.2O).sub.1-6CH.sub.2CH.sub.2C(O) OR, --(CH.sub.2CH.sub.2O).sub.1-6CH.sub.2CH.sub.2NRR, --C.sub.1-6alkyl, C.sub.6-14aryl, --C.sub.1-6alkylene-C.sub.6-14aryl and --C.sub.5-14heteroaryl; or R.sup.14 and R.sup.15, together with the atom or atoms to which they are joined, form a C.sub.3-10heterocyclyl ring, wherein R.sup.14, R.sup.15, or both, or a ring formed with R.sup.14 and R.sup.15, are optionally substituted with --(C(R).sub.2).sub.m--R.sup.18 where each R.sup.18 is independently selected from (i) --NRR, (ii) --C(NRR)(C(O)OR), (iii) --S--R, (iv) aryl or heteroaryl optionally substituted with one or more of halogen, --CF.sub.3, --(C(R).sub.2).sub.m--NRR or C(R).sub.2).sub.m--SO.sub.2NRR, (v) --SO.sub.2R, (vi) --S--S--C.sub.1-6alkyl-C(O)OR, (vii) --SO.sub.2NRR, (viii) --C(O)NRR, (ix) --C(O)OR, (x) --C.sub.4-6 cycloalkyl optionally substituted with --NRR, --SO.sub.2NRR or --NR--C(O) (CH.sub.2).sub.0-6NRR, (xi) --R, (xii) --OR, (xiii) --N(R)NRR, (xiv) --C(O)N(R)NRR, (xv) --(C(R).sub.2).sub.m--O--NRR and (xiv) --S--S--C.sub.1-6alkyl-NRR; each R.sup.14' is independently selected from the group consisting of: a bond, --NR--, --C.sub.3-10carbocyclyl-, --C.sub.3-10heterocyclyl-, --(CH.sub.2CH.sub.2O).sub.1-6CH.sub.2CH.sub.2C(O)OR', --(CH.sub.2CH.sub.2O).sub.1-6CH.sub.2CH.sub.2NR--, and --C.sub.1-6alkylene-, wherein R.sup.14' is optionally substituted with --(C(R).sub.2).sub.m--R.sup.18 where each R.sup.18 is independently selected from (i) --NRR, (ii) --C(NRR)(C(O)OR), (iii) --S--R, (iv) aryl or heteroaryl optionally substituted with one or more of halogen, --CF.sub.3, --NRR or --SO.sub.2NRR, (v) --SO.sub.2R, (vi) --S--S--C.sub.1-6alkyl-C(O)OR, (vii) --SO.sub.2NRR, (viii) --C(O)NRR, (ix) --C(O)OR, (x) --C.sub.4-6 cycloalkyl optionally substituted with --NRR, --SO.sub.2NRR or --NR--C(O)(CH.sub.2).sub.0-6NRR, (xi) --R, (xii) --OR, (xiii) --N(R)NRR, (xiv) --C(O)N(R)NRR, (xv) --(C(R).sub.2).sub.m--O--NRR and (xiv) --S--S--C.sub.1-6alkyl-NRR; each R is independently selected from the group consisting of: hydrogen and --C.sub.1-6alkyl; each R' is independently selected from --H, C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 heteroalkyl and aryl; each R'' is independently selected from the group consisting of: a bond and --C.sub.1-6alkylene-; and b is 1-20; and each m is independently 0, 1, 2 or 3, said amount being effective to treat cancer.

7. The method of claim 6, wherein said cancer is selected from carcinomas of the bladder, breast, cervix, colon, endometrium, kidney, lung, esophagus, ovary, prostate, pancreas, skin, stomach, and testes, leukemias and lymphomas.

8. The method of claim 5, wherein said compound is selected from the group consisting of: ##STR00340## ##STR00341## ##STR00342## ##STR00343## ##STR00344## ##STR00345## ##STR00346## ##STR00347## ##STR00348## ##STR00349## ##STR00350## ##STR00351## ##STR00352## where --NH--X, --NH--C(O)--X or --S--X represents the antibody AB; or a pharmaceutically acceptable salt thereof.

9. The method of claim 5, wherein the antibody AB is selected from: trastuzumab, trastuzumab mutants, oregovomab, edrecolomab, cetuximab, a humanized monoclonal antibody to the vitronectin receptor (.alpha..sub.v.beta..sub.3), alemtuzumab, a humanized anti-HLA-DR antibody for the treatment of non-Hodgkin's lymphoma, 1311 Lym-1, a murine anti-HLA-Dr10 antibody for the treatment of non-Hodgkin's lymphoma, a humanized anti-CD2 mAb for the treatment of Hodgkin's Disease or non-Hodgkin's lymphoma, labetuzumab, bevacizumab, ibritumomab tiuxetan, ofatumumab, panitumumab, rituximab, tositumomab, ipilimumab, gemtuzumab, a humanized monoclonal antibody to the oncofecal protein receptor 5T4, and an antibody to CD11b receptor.

Details for Patent 9,504,669

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Pfizer Inc. (New York, NY) 2032-11-05 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Pfizer Inc. (New York, NY) 2032-11-05 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Pfizer Inc. (New York, NY) 2032-11-05 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Pfizer Inc. (New York, NY) 2032-11-05 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Pfizer Inc. (New York, NY) 2032-11-05 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial Pfizer Inc. (New York, NY) 2032-11-05 RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial Pfizer Inc. (New York, NY) 2032-11-05 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,504,669

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Mallinckrodt
Merck
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.